Last reviewed · How we verify
NCT05147181: CHOPIN
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
trial in Hereditary Angioedema (HAE) in 48 participants. Completed in 13 November 2025.
13 November 2025
Quick facts
| Lead sponsor | Takeda |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 11 March 2022 |
| Primary completion | 13 November 2025 |
| Estimated completion | 13 November 2025 |
| Sites | 14 locations across Poland |
Conditions studied
- Hereditary Angioedema (HAE) — all drugs for Hereditary Angioedema (HAE) →
Sponsor
Takeda — full company profile →
Who can join
12 and older, any sex, with Hereditary Angioedema (HAE). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of this study is to learn about how many persons with HAE type I or type II are attack-free when treated with lanadelumab in real life, how many attacks occur and how many of these attacks need rescue treatment and about the nature of HAE attacks. Participants will need to visit their doctor 5 times in total as part of this study. The visits are planned every 6 months. Participants will also be asked to fill out questionnaires as part of this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05147181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hereditary Angioedema (HAE)
Currently open trials in the same condition.
- NCT07251933 — A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries · recruiting
- NCT07046806 — Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients · Phase 1, PHASE2 · recruiting
- NCT06806618 — HAE Burden and Crisis Management · recruiting
- NCT06846398 — A Phase 2 in Adult Subjects With Hereditary Angioedema · Phase 2 · active not recruiting
- NCT05469789 — A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) · active not recruiting
Other Takeda trials
Trials by the same sponsor.
- NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
- NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
- NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
- NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
- NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05147181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Takeda
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05147181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing